Evaluation of the impact of sodium lauryl sulfate source variability on solid oral dosage form development

Drug Development and Industrial Pharmacy

Volumn 36, Issue 12, 2010, Pages 1486-1496

  Qiang, Dongmei ^a   Gunn, Jocelyn A ^a   Schultz, Leon ^a   Li, Z Jane ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Critical micelle concentration; Dissolution; Micronization; Poorly soluble drug; Sodium lauryl sulfate; Solid dosage form; Solubility; Supersaturation; Surface tension; Wet granulation

Indexed keywords

DODECYL SULFATE SODIUM;

AQUEOUS SOLUTION; ARTICLE; CRITICAL MICELLE CONCENTRATION; DRUG GRANULATION; DRUG SOLUBILITY; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SOLUBILIZATION; SURFACE TENSION;

AZEPINES; CHEMISTRY, PHARMACEUTICAL; MICELLES; PARTICLE SIZE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE TENSION; SURFACE-ACTIVE AGENTS; TABLETS;

EID: 78149385377     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.488647     Document Type: Article

References (43)

1. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19(7):921-5.
2. Rasenack N, Muller BW. (2005). Poorly water-soluble drugs for oral delivery-A challenge for pharmaceutical development. Pharm Ind, 67(3):323-6.
3. Mallick S, Pattnaik S, Swain K. (2007). Current perspectives of solubilization: Potential for improved bioavailability. Drug Dev Ind Pharm, 33:865-73.
4. Badawy SI, Gray DB, Zhao F. (2006). Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res, 23(5):989-96.
5. Riis T, Bauer-Brandl A, Wagner T. (2007). pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm, 65(1):78-84.
6. Devarakonda B, Otto DP, Judefeind AA. (2007). Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm, 345(1-2):142-53.
7. Nie SF, Fan XW, Peng Y. (2007). In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin. Arch Pharm Res, 30(8):991-1001.
8. Zahedi P, Lee PI. (2007). Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels. Eur J Pharm Biopharm, 65(3):320-8.
9. Serajuddin ATM. (1999). Solid dispersion of poorly-soluble drugs: Early promises, subsequent problems and recent breakthroughs. J Pharm Sci, 88(10):1058-66.
10. Law D, Schmitt EA, Marsh KC. (2004). Ritonavior-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci, 93(3):563-70.
11. Emara LH, Badr RM, Elbary AA. (2002). Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev Ind Pharm, 28(7):795-807.
12. Gupta P, Bansal AK. (2005). Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility. Pharmazie, 60(11):830-6.
13. Blagden N, de Matas M, Gavan PT. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev, 59(7):617-30.
14. Thanos CG, Liu Z, Goddard M. (2003). Enhancing the oral bioavailability of the poorly soluble drug dicumarol with a bioadhesive polymer. J Pharm Sci, 92(8):1677-89.
15. Oh DM, Curl RL, Yong CS, Amidon GL. (1995). Effect of micronization on the extent of drug absorption from suspensions in humans. Arch Pharm Res, 18(6):427-33.
16. Thanos CG, Liu Z, Reineke J, Edwards E, Mathiowitz E. (2003). Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride. Pharm Res, 20(7):1093-100.
17. Kawakami K, Oda N, Miyoshi K. (2006). Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur J Pharm Sci, 28(1-2):7-14.
18. Li DX, Han MJ, Balakrishnan P, Yan YD, Choi HG. (2010). Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Arch Pharm Res, 33(1):95-101.
19. Gao P, Guyton ME, Huang TH. (2004). Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm, 30(2):221-9.
20. Rao VM, Nerurkar M, Pinnamaneni S. (2006). Co-solubilization of poorly soluble drugs by micellization and complexation. Int J Pharm, 319(1-2):98-106.
21. Dangi JS, Vyas SP, Dixit VK. (1998). The role of mixed micelles in drug delivery. I. Solubilization. Drug Dev Ind Pharm, 24(7):681-4.
22. Patel R, Buckton G, Gaisford S. (2007). The use of isothermal titration calorimetry to assess the solubility enhancement of simvastatin by a range of surfactants. Thermochim Acta, 456(2):106-13.
23. Joshi VY, Sawant MR. (2006). Study on dissolution rate enhancement of poorly water soluble drug: Contributions of solubility enhancement and relatively low micelle diffusivity. J Dispers Sci Technol, 27(8):1141-50.
24. Bhat PA, Dar AA, Rather GM. (2008). Solubilization capabilities of some cationic, anionic, and nonionic surfactants toward the poorly water-soluble antibiotic drug erythromycin. J Chem Eng Data, 53(6):1271-7.
25. Strickley RG. (2004). Solubilizing excipients in oral and injectable formulations. Pharm Res, 21(2):201-30.
26. Branchu S, Rogueda PG, Plumb AP, Cook WG. (2007). A decision- support tool for the formulation of orally active, poorly soluble compounds. Eur J Pharm Sci, 33(2):128-39.
27. Sheng JJ, Kasim NA, Chandrasekharan R, Amidon GL. (2006). Solubilization and dissolution of insoluble weak acid, ketoprofen: Effects of pH combined with surfactant. Eur J Pharm Sci, 29(3-4):306-14.
28. Woo JS, Piao MG, Li DX. (2007). Development of cyclosporin Aloaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm, 345(1-2):134-41.
29. Ruddy SB, Matuszewska BK, Grim YA, Ostovic D, Storey DE. (1999). Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly-soluble immunosuppressive agent. Int J Pharm, 182:173-86.
30. Fairnerman VB, Miller R. (1995). Dynamic surface tensions of surfactant mixtures at water-air interface. Colloids Surf A, 97:65-82.
31. Crison JR, Weiner ND, Amidon GL. (1997). Dissolution media for in vitro testing of water-insoluble drugs: Effects of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J Pharm Sci, 86(3):384-8.
32. Manabe M, Kikuch S, Nakano Y, Kikuchi Y, Tokunaga S, Koda M. (1984). The effect of 1-alkanols on the critical micelle concentration of sodium alkylsulfates. Niihama Kogyo Koto Senmon Gakko Kiyo, Rikogaku-hen, 20:51-7.
33. Javadian S, Gharibi H, Sohrabi B. (2008). Determination of the physico-chemical parameters and aggregation number of surfactant in micelles in binary alcohol-water mixtures. J Mol Liq, 137:74-9.
34. Manabe M, Koda M. (1978). The effect of poly(oxyethylene) alkyl ethers, alkanediols, and alkanols on the critical micelle concentration of sodium dodecyl sulfate. Bull Chem Soc Jpn, 51(6):1599-601.
35. Baudium P, Basse A, Touraud D. (2005). Effect of short nonionic amphiphiles derived from ethylene and propylene glycol alkyl ethers on the CMC of SDS. Colloids Surf A, 270-271:8-12.
36. Ohki K, Tokiwa F. (1969). Physicochemical properties of sulfate- type and ether sulfate-type surfactants. Effect of alkyl chain structure. Nippon Kagaku Zasshi, 90(8):760-4.
37. Yalkowsky SH. (1999). Solubility and solubilization in aqueous media. New York: Oxford University Press, 236-319.
38. Iveson SM, Litster JD, Hapgood K, Ennis BJ. (2001). Nucleation, growth and breakage phenomena in agitated wet granulation processes: A review. Powder Technol, 117:3-39.
39. Rajniak P, Mancinelli C, Farber L. (2007). Experimental study of wet granulation in fluidized bed: Impact of the binder properties on the granule morphology. Int J Pharm, 334:92-102.
40. Jaiyeoba KT, Spring MS. (1980). The granulation of ternary mixtures: The effect of wettability of the powders. J Pharm Pharmacol, 32:386-8.
41. Di Martino P, Censi R, Malaj L, Martelli S, Joiris E, Barthelemy C. (2007). Influence of metronidazole particle properties on granules prepared in a high-shear mixer-granulator. Drug Dev Ind Pharm, 33(2):121-31.
42. Gluba T, Heim A, Kochanski B. (1990). Application of the theory of moments in the estimation of powder granulation of different wettabilities. Powder Handl Process, 2:323-6.
43. Pepin X, Blanchon S, Couarraze G. (2001). Power consumption profiles in high-shear wet granulation. II. Predicting the over wetting point from a spreading energy. J Pharm Sci, 90(3):332-9.